INTRODUCTION
============

Cholera toxin (CT) secreted by *Vibrio cholera* is a causative agent for massive secretory diarrhea. The CT holotoxin consists of catalytic (CTA) and receptor-binding (CTB) subunits. To initiate entry into intestinal epithelial cells, CTB binds to the ganglioside GM1 receptor, transporting the holotoxin in a retrograde manner to the endoplasmic reticulum (ER; [@B6]). Here CT coopts an intrinsic quality control process called ER-associated degradation (ERAD), which normally ejects misfolded ER substrates to the cytosol, where they are degraded by the proteasome ([@B17]). When CT hijacks the ERAD pathway, CTA becomes reduced by a cellular reductase, generating the CTA1 subunit, which retrotranslocates to the cytosol. However, in contrast to the fate of a misfolded substrate, CTA1 evades proteasomal degradation in the cytosol and induces toxicity ([@B34]). The molecular mechanism by which CT hijacks specific components of the ERAD machinery to reach the cytosol is slowly emerging.

The central ERAD machinery is composed of an E3 ubiquitin ligase complexed with different ER lumenal, membrane, and cytosolic adapters ([@B19]; [@B7]); this complex acts coordinately to mobilize various misfolded substrates across the ER membrane. Our laboratory and others demonstrated that CT targets to the E3 ubiquitin ligase Hrd1 ([@B3]) and its membrane adapters Derlin-1 ([@B2]; [@B8]) and Sel1L ([@B44]) to initiate retrotranslocation. By use of the CRISPR-mediated gene control strategy, the Hrd1-Sel1L complex was recently confirmed to be important for facilitating CT retrotranslocation ([@B14]). To help target CT for retrotranslocation, the Sel1L binding partner ERdj5, an ER-resident J-protein, stimulates the intrinsic ATPase activity of the Hsp70 chaperone BiP to form ADP-BiP. Because ADP-BiP exhibits a high affinity for substrates ([@B23]), it captures CT efficiently. By juxtaposing ERdj5 next to Hrd1 via ERdj5\'s interaction with Sel1L ([@B44]), capture of CT by BiP occurs proximal to the ERAD machinery. A previous study suggested that the BiP--toxin interaction functionally renders the toxin competent for retrotranslocation ([@B45]).

Because BiP is not retrotranslocated with the toxin, CTA must be released from BiP before the toxin reaches the cytosol. Substrate release from BiP normally occurs when ADP-BiP is converted to ATP-BiP, which displays low affinity for substrates. Because conversion of ADP-BiP to ATP-BiP is catalyzed by nucleotide exchange factors (NEFs; [@B23]; [@B31]), we hypothesize that NEFs facilitate CTA release from BiP to enable toxin retrotranslocation.

Grp170 and Sil1 are ER-resident NEFs ([@B42]; [@B1]; [@B16]; [@B46]). Grp170 is considered a distinct member of the canonical Hsp70 protein family, whereas Sil1 is not. A unique feature of Grp170 is that, in addition to its recognized NEF activity, it contains a C-terminal holdase domain that functions to prevent protein aggregation ([@B9]; [@B32]); Sil1 lacks this domain and activity. Of interest, a recent report found Grp170\'s holdase but not NEF activity to be responsible for promoting retrotranslocation of a sodium channel that acts as an ERAD substrate in mammalian cells ([@B4]). In the case of Sil1, although absence of *SIL1* in yeast mildly disrupted ERAD ([@B40]), it is unclear whether Sil1\'s NEF activity is responsible for this phenotype. Thus whether the NEF activity of Grp170 or Sil1 exerts any role in CTA1 retrotranslocation is unknown.

In this study, we used a cell-based, semipermeabilized system in the context of loss-and gain-of function approaches, coupled with biochemical strategies, to demonstrate that Grp170 and Sil1 regulate CTA release from BiP to facilitate toxin retrotranslocation. Moreover, after release from BiP, our data suggest that the toxin is handed off to protein disulfide isomerase (PDI), an ER redox chaperone known to unfold CTA1 that primes the toxin for translocation across the Hrd1-Sel1L complex. These findings thus reveal additional insights into how the toxin is delivered to the ERAD machinery.

RESULTS
=======

Grp170 and Sil1 knockdown decreases CTA1 retrotranslocation
-----------------------------------------------------------

To evaluate the role of Grp170 and Sil1 in promoting CTA1 retrotranslocation, we used two distinct small interfering RNAs (siRNAs) against each protein (Grp170 siRNA \#1 and \#2, and Sil1 siRNA \#1 and \#2) to silence their expression in 293T cells. When compared with cells treated with a control siRNA (i.e., scrambled), Grp170 was efficiently down-regulated by Grp170 siRNA \#1 and \#2 ([Figure 1A](#F1){ref-type="fig"}, top, compare lanes 2 and 3 to lanes 1, 4, and 5). Similarly, Sil1 was silenced effectively by Sil1 siRNA \#1 and \#2 ([Figure 1A](#F1){ref-type="fig"}, second panel, compare lanes 4 and 5 to lanes 1--3). Sil1 expression was unperturbed by the Grp170-specific siRNAs ([Figure 1A](#F1){ref-type="fig"}, second panel, compare lanes 2 and 3 to lane 1), whereas Grp170 expression was not disrupted by the Sil1-directed siRNAs ([Figure 1A](#F1){ref-type="fig"}, top, compare lanes 4 and 5 to lane 1). Neither ER stress marker BiP nor PDI increased when Grp170 or Sil1 was knocked down ([Figure 1A](#F1){ref-type="fig"}, third and fourth panels, compare lanes 2--5 to lane 1). Moreover, we found no evidence of XBP1 splicing (a sensitive indicator of ER stress induction) when Grp170 or Sil1 was silenced ([Figure 1A](#F1){ref-type="fig"}, compare lanes 8--11 with lane 7), in contrast to cells treated with the chemical ER stress inducer dithiothreitol (DTT; [Figure 1A](#F1){ref-type="fig"}, compare lane 6 with lane 7). Thus Grp170 and Sil1 can be specifically and efficiently down-regulated without causing massive ER stress.

![Grp170 and Sil1 knockdown decreases CTA1 retrotranslocation. (A) Lanes 1--5, WCEs derived from 293T cells transfected with the indicated siRNA were analyzed by SDS--PAGE and immunoblotted with the indicated antibodies and the film developed by using ECL. All immunoblots were developed using this method. Lanes 6--11, reverse-transcription PCR analysis of the unspliced (u) and spliced (s) forms of the XBP1 mRNA derived from cells transfected with the indicated siRNA and treated with or without DTT as indicated. (B) Cells were semipermeabilized with digitonin and subjected to centrifugation, and the generated supernatant and pellet fractions were analyzed for the presence of the cytosolic Hsp90 and the ER-resident PDI markers. This fractionation method is used in the retrotranslocation assay. (C) Cells transfected with the indicated siRNA were incubated with CT (10 nM) for 90 min and subjected to the retrotranslocation assay as presented in B. Both the supernatant and pellet fractions were analyzed by SDS--PAGE and immunoblotted with the indicated antibodies. (D) The intensity of the supernatant CTA1 band in C was quantified by ImageJ (National Institutes of Health, Bethesda, MD) using scans of films after ECL. Mean of three independent experiments. A two-tailed *t* test was used. Error bars, ± SD. (E) In the rescue experiment, cells transfected with scrambled or Grp170 siRNA \#1 were transfected with either Grp170-FLAG\* or FLAG-Sil1, as indicated. After intoxication with CT (10 nM) for 90 min, cells were processed and analyzed as in C. (F) In a rescue experiment similar to E, cells transfected with scrambled or Sil1 siRNA \#2 were transfected with either Grp170-FLAG or FLAG-Sil1\*, as indicated. After intoxication with CT (10 nM) for 90 min, cells were processed and analyzed as in C. (G) Cells were cotransfected with Δ F508 CFTR and a scrambled siRNA, Grp170 siRNA \#2, or Sil1 siRNA \#1. Δ F508 CFTR was immunoprecipitated from the resulting WCE, and samples were subjected to immunoblotting with an antibody against CFTR. The black line indicates that an intervening lane from the same immunoblot has been spliced out.](2181fig1){#F1}

To determine whether silencing the NEFs affects CTA1 arrival to the cytosol from the ER, we relied on a previously established semipermeabilized retrotranslocation assay that monitors toxin ER-to-cytosol transport ([@B12]; [@B3]; [@B44]). This assay has been used by other laboratories to examine CTA1 retrotranslocation ([@B39]; [@B43]; [@B28]), as well as by us and other laboratories to investigate ER-to-cytosol transport of the viral pathogen SV40 ([@B20]; [@B13]). Briefly, cells were intoxicated with CT for 90 min and treated with a low digitonin concentration to permeabilize the plasma membrane without affecting internal membranes. Subsequent high-speed centrifugation of the sample generates a supernatant and a pellet fraction. The supernatant fraction should harbor cytosolic proteins and any toxin that underwent retrotranslocation to the cytosol. In contrast, the pellet fraction should contain membranes, including the ER membrane, and any toxin that has reached the ER but has not retrotranslocated to the cytosol, as well as toxin present in other membranous compartments. Using this strategy, we detected the cytosolic Hsp90 in the supernatant fraction ([Figure 1B](#F1){ref-type="fig"}, top, compare lane 1 with lane 2), whereas the ER-resident protein PDI fractionated to the pellet fraction ([Figure 1B](#F1){ref-type="fig"}, bottom, compare lane 2 with lane 1). These results verify the integrity of the fractionation approach.

Of importance, we found that silencing Grp170 or Sil1 with either siRNA markedly decreased the CTA1 level in the supernatant when compared with the scrambled siRNA ([Figure 1C](#F1){ref-type="fig"}, panel, compare lanes 2--5 to lane 1). We quantified these results from scans of films following enhanced chemiluminescence (ECL) as before ([@B12]; [@B3]; [@B44]) and found that knocking down Grp170 decreased CTA1 retrotranslocation by ∼50--60%, whereas down-regulating Sil1 impaired toxin retrotranslocation by 60--75% ([Figure 1D](#F1){ref-type="fig"}, black bars). In a rescue experiment, expression of either a siRNA-resistant wild-type (WT) Grp170 FLAG-tagged construct (i.e., Grp170-FLAG**\***; [Figure 1E](#F1){ref-type="fig"}, third and fifth panels, lane 3) or a WT FLAG-tagged Sil1 construct (i.e., FLAG-Sil1\*; [Figure 1E](#F1){ref-type="fig"}, fourth and fifth panels, lane 4) partially restored the CTA1 supernatant level derived from cells depleted of Grp170 ([Figure 1E](#F1){ref-type="fig"}, top, compare lanes 3 and 4 to lane 2). Similarly, in Sil1-knockdown cells, expression of Grp170-FLAG ([Figure 1F](#F1){ref-type="fig"}, third and fifth panels, lane 3) or a siRNA-resistant WT FLAG-tagged Sil1 construct (i.e., FLAG-Sil1\*; [Figure 1F](#F1){ref-type="fig"}, fourth and fifth panels, lane 4) partially restored the CTA1 level in the supernatant fraction ([Figure 1F](#F1){ref-type="fig"}, top, compare lanes 3 and 4 with 2). These findings demonstrate that Grp170 and Sil1 are crucial for promoting CTA1 retrotranslocation and that their activities appear interchangeable during this process.

Silencing Grp170 or Sil1 does not appear to globally affect ERAD. This is because Grp170 or Sil1 knockdown had no effect on the steady-state level of the ERAD membrane substrate Δ F508 CFTR (cystic fibrosis transmembrane conductance regulator; [Figure 1G](#F1){ref-type="fig"}, compare lanes 2 and 3 with lane 1), consistent with the yeast Grp170 homologue Lhs1p not controlling ERAD of CFTR ([@B4]). In addition, in the case of Sil1, we recently found that ER-to-cytosol transport of the viral pathogen SV40 is unaffected by Sil1 knockdown ([@B21]).

Grp170 and Sil1 overexpression stimulates CTA1 retrotranslocation
-----------------------------------------------------------------

To complement the loss-of-function approach, we performed gain-of-function experiments to further probe a role of the NEFs in facilitating toxin retrotranslocation. When cells transfected with vector WT Grp170 containing a FLAG tag (i.e., Grp170-FLAG) or FLAG-Sil1 ([Figure 2A](#F2){ref-type="fig"}, top, lanes 1--3) were intoxicated with CT for 90 min and subjected to the cell-based retrotranslocation assay, we found that overexpression of either Grp170 or Sil1 increased the CTA1 level in the supernatant fraction when compared with vector control ([Figure 2B](#F2){ref-type="fig"}, top, compare lanes 2 and 3 to lane 1; quantified in [Figure 2C](#F2){ref-type="fig"}, black bars). Overexpressing the NEFs also enhanced the CTA1 level in the supernatant when CT was intoxicated for 60 min, albeit more modestly (quantified in [Figure 2C](#F2){ref-type="fig"}, gray bars). In contrast to overexpression of Grp170-FLAG, overexpression of a NEF-defective Grp170 construct (i.e., G41L Grp170-FLAG; [@B21]; [Figure 2D](#F2){ref-type="fig"}, fifth panel, lane 3) did not enhance the CTA1 supernatant level when compared with the vector control ([Figure 2D](#F2){ref-type="fig"}, top, compare lane 3 with lane 2); in fact, a moderate decrease in the toxin level in the supernatant fraction was reliably observed in cells expressing G41L Grp170-FLAG when compared with cells expressing the vector ([Figure 2D](#F2){ref-type="fig"}, top, compare lane 3 with lane 1). Although a specific NEF-defective Sil1 mutant has yet to be shown, a yeast Sil1-Kar2p (homologue of mammalian BiP) complex structure suggests that Sil1 induces a conformational change in Kar2p that promotes release of ADP ([@B46]). Because the yeast H163A Sil1 mutant was found to be defective in Kar2p binding ([@B46]), it unlikely imparts NEF activity against Kar2p. Accordingly, we generated the corresponding mutant in human Sil1 (i.e., FLAG-H241A Sil1) and found that, by contrast to FLAG-Sil1, precipitation of FLAG-H241A Sil1 did not pull down endogenous BiP ([Figure 2E](#F2){ref-type="fig"}, top, compare lane 3 with lane 2). Of importance, only overexpression of FLAG-Sil1 ([Figure 2F](#F2){ref-type="fig"}, fifth panel, lane 2) but not FLAG-H241A Sil1 ([Figure 2F](#F2){ref-type="fig"}, fifth panel, lane 3) stimulated toxin retrotranslocation ([Figure 2F](#F2){ref-type="fig"}, top, compare lane 2 with lanes 1 and 3); again, a decrease in the toxin level in the supernatant fraction was observed in cells expressing FLAG-H241A Sil1 when compared with cells expressing the vector ([Figure 2F](#F2){ref-type="fig"}, top, compare lane 3 with lane 1). Collectively these data reinforce a crucial function of Grp170 and Sil1 in mediating CTA1 ER-to-cytosol transport and suggest that the inherent NEF activities of these factors are responsible for driving this reaction.

![Grp170 and Sil1 overexpression stimulates CTA1 retrotranslocation. (A) WCEs derived from 293T cells intoxicated with CT for 90 min and transfected with the indicated construct were analyzed by SDS--PAGE and immunoblotted with the indicated antibodies. (B) Cells intoxicated with CT for 90 min and expressing the constructs as in A were subjected to the retrotranslocation assay and analyzed as in [Figure 1C](#F1){ref-type="fig"}. (C) The supernatant CTA1 band intensity in B was quantified (black bars) as in [Figure 1D](#F1){ref-type="fig"}. In addition, quantification of the supernatant CTA1 band intensity derived from cells treated with CT for 60 min is presented in the gray bars. Mean of three independent experiments. A two-tailed *t* test is shown for the 90-min intoxication experiments. Error bars, ± SD. (D) As in B, except cells were transfected with the indicated construct. (E) WCEs derived from 293T cells transfected with the indicated constructs were subjected to immunoprecipitation using FLAG antibody--conjugated beads. The precipitated samples were analyzed by SDS--PAGE and immunoblotted with the indicated antibodies. (F) As in B, except that cells were transfected with the indicated construct.](2181fig2){#F2}

Knockdown of Grp170 or Sil1 decreases toxin release from BiP
------------------------------------------------------------

We reasoned that, if Grp170 and Sil1 exert their NEF functions to promote release of CTA from BiP, altering their expression level should concomitantly affect the extent of the toxin--BiP interaction. To decrease the NEF expression level, we silenced Grp170 or Sil1 using Grp170 siRNA \#1 or Sil1 siRNA \#1 and incubated the knocked-down cells with or without CT. As before ([Figure 1A](#F1){ref-type="fig"}), Grp170 siRNA \#1 efficiently down-regulated Grp170 without disrupting the Sil1 level ([Figure 3A](#F3){ref-type="fig"}, compare top to second panel), whereas Sil1 siRNA \#1 silenced Sil1 markedly without perturbing Grp170\'s level ([Figure 3A](#F3){ref-type="fig"}, compare the second panel to the top panel). Under these conditions, the whole-cell extracts (WCEs) derived from cells were incubated with an antibody against CTA and the immunoprecipitates subjected to SDS--PAGE, followed by immunoblotting with either a BiP or CTA antibody. BiP was only found in the immunoprecipitates from CT-intoxicated cells ([Figure 3B](#F3){ref-type="fig"}, top and second panels; compare lanes 4--6 with lanes 1--3), indicating that BiP specifically engages CTA, as previously observed ([@B44]). (Only CTA1 appears in the immunoblot because the sample buffer contained the reducing agent β-mercaptoethanol to efficiently detect the toxin.) Of importance, silencing Grp170 increased the level of BiP that coprecipitated with CTA ([Figure 3B](#F3){ref-type="fig"}, top, compare lane 5 with lane 4). A modestly higher level of BiP consistently coprecipitated with CTA in cells lacking Sil1 ([Figure 3B](#F3){ref-type="fig"}, top, compare lane 6 with lane 4). These findings indicate that decreasing the levels of Grp170 and Sil1 preferentially trapped the toxin on BiP, consistent with the posited role of these NEFs in releasing CTA from BiP. It is important to note that the less efficient release of CTA from BiP is consistent with a decrease in toxin retrotranslocation found under NEF-knockdown conditions ([Figure 1](#F1){ref-type="fig"}).

![Knockdown of Grp170 or Sil1 decreases toxin release from BiP. (A) WCEs derived from 293T cells transfected with the indicated siRNA and intoxicated with or without CT were analyzed by SDS--PAGE and immunoblotted with the indicated antibodies. (B) WCEs derived from cells in A were subjected to immunoprecipitation using an antibody against CTA. The immunoprecipitates were analyzed by reducing SDS--PAGE and immunoblotted against the indicated antibodies.](2181fig3){#F3}

Overexpressing Grp170 or Sil1 markedly stimulates toxin release from BiP
------------------------------------------------------------------------

Because knockdown of the NEFs traps the toxin on BiP, we asked whether overexpressing the NEFs ([Figure 4A](#F4){ref-type="fig"}, top) might stimulate CTA release from BiP and found that it did ([Figure 4B](#F4){ref-type="fig"}, top, compare lanes 5 and 6 to lane 4). The enhanced release of toxin from BiP likely explains why toxin retrotranslocation increased under the overexpression conditions ([Figure 2](#F2){ref-type="fig"}). As a control, expressing G41L Grp170-FLAG or FLAG-H214A Sil1 did not enhance toxin release from BiP ([Figure 4C](#F4){ref-type="fig"}, top, compare lanes 2 and 3 with lane 1), in line with the observation that their overexpression did not stimulate toxin retrotranslocation ([Figure 2](#F2){ref-type="fig"}). In fact, overexpressing mutant Sil1 modestly trapped the toxin to BiP ([Figure 4C](#F4){ref-type="fig"}, top, compare lane 3 with lane 1), consistent with the ability of this construct to inhibit CTA1 retrotranslocation when overexpressed ([Figure 2F](#F2){ref-type="fig"}, top, compare lane 3 with lane 1). Because overexpressing either WT Grp170 or Sil1 increased toxin disengagement from BiP and retrotranslocation, Grp170 and Sil1 likely use their NEF activities to promote toxin release from BiP in order to promote the toxin for retrotranslocation.

![Overexpressing Grp170 or Sil1 markedly stimulates toxin release from BiP. (A) WCEs derived from 293T cells transfected with the indicated construct and intoxicated with or without CT were analyzed by SDS--PAGE and immunoblotted with the indicated antibodies. (B) WCEs derived from cells in A were subjected to immunoprecipitation using an antibody against CTA. The immunoprecipitates were analyzed by reducing SDS--PAGE and immunoblotted against the indicated antibodies. (C) As in B, except that G41L Grp170-FLAG or FLAG-H214A Sil1 was transfected instead of the respective WT counterpart.](2181fig4){#F4}

CTA is transferred to PDI upon NEF-dependent release from BiP
-------------------------------------------------------------

We previously hypothesized that, once the toxin is captured by and released from BiP, it is transferred to PDI ([@B44]), which unfolds the toxin ([@B41]; [@B11]; [@B43]), a reaction required for its retrotranslocation ([@B12]). To test this possibility, we knocked down Grp170 (using Grp170 siRNA \#1) or Sil1 (using Sil1 siRNA \#1) to decrease toxin release from BiP ([Figure 3B](#F3){ref-type="fig"}). Under this condition, PDI binds to the toxin less efficiently ([Figure 5A](#F5){ref-type="fig"}, top, compare lanes 2 and 3 with lane 1), suggesting that the toxin--PDI interaction occurs downstream of toxin release from BiP. Conversely, when PDI was down-regulated ([Figure 5B](#F5){ref-type="fig"}, fourth panel, compare lane 2 with lane 1), the toxin accumulates on BiP ([Figure 5B](#F5){ref-type="fig"}, top, compare lane 2 with lane 1). Presumably, when the PDI level is lowered, the released toxin inefficiently transfers to PDI and as a consequence reengages BiP via the action of the J-protein ERdj5. These data are consistent with a scenario in which the toxin is handed off to PDI upon release from BiP.

![CTA is transferred to PDI upon NEF-dependent release from BiP. (A) WCEs derived from cells expressing the indicated siRNA were incubated with an antibody against CTA. The immunoprecipitates were subjected to reducing SDS--PAGE and immunoblotted with the indicated antibodies. (B) As in A, except that a siRNA against PDI was used, and the immunoblot was probed using a BiP antibody. (C) Model depicting the role of the ER-resident NEFs Grp170 and Sil1 during CTA1 retrotranslocation. In the ER, CT targets to the ERAD machinery formed by the Hrd1/Sel1L/Derlin-1 complex partly due to the activity of the Sel1L-binding partner ERdj5. This J-protein enables BiP to capture CT by stimulating BiP\'s intrinsic ATPase activity. Grp170 and Sil1 impose their NEF activities on BiP, triggering CTA to disengage from BiP (arrow). Next CTA is delivered to PDI, which in turn unfolds the toxin. The identity of an ER reductase that generates the CTA1 peptide from CTA is unknown. In the final step, unfolded CTA1 translocates across the Hrd1/Sel1L/Derlin-1 complex to reach the cytosol.](2181fig5){#F5}

DISCUSSION
==========

CT is postulated to disguise as a misfolded protein when it reaches the ER, coopting the ERAD pathway to enter the cytosol and induce toxicity ([@B17]). Not surprisingly, CT engages BiP ([@B45]; [@B44]), an ER-resident chaperone that normally binds to misfolded clients to prevent them from aggregation ([@B29]; [@B22]). Once the toxin binds to BiP, it must be released from BiP in order to cross the retrotranslocation machinery on the ER membrane to access the cytosol. The identity of the release factors that trigger toxin release from BiP is unknown.

In this study, we pinpoint two NEFs that promote toxin release from BiP to facilitate retrotranslocation. The major conclusions of our findings are summarized in [Figure 5C](#F5){ref-type="fig"}. When CT reaches the ER from the cell surface, it targets to the Hrd1/Sel1L/Derlin-1 membrane complex, in part due to the activity of the Sel1L-interacting protein ERdj5 ([@B44]). This J-protein stimulates the BiP ATPase activity, enabling ADP-BiP to capture the CT holotoxin ([@B44]). To release the captured toxin, this study demonstrates that the ER-resident NEFs Grp170 and Sil1 cause CTA to be released from BiP, presumably by converting ADP-BiP to ATP-BiP ([Figure 5C](#F5){ref-type="fig"}, arrow). The released CTA is then transferred to PDI, which unfolds the toxin. Precisely when an ER reductase reduces CTA to generate the CTA1 peptide is unclear. Regardless, the unfolded CTA1 peptide is transferred to the Hrd1/Sel1L/Derlin-1 complex for translocation across the ER membrane. The driving force that in turn pulls the toxin into the cytosol is unknown but may involve an unidentified GTPase ([@B27]).

The present study suggests that the NEF activities of both Grp170 and Sil1 are hijacked during retrotranslocation of CTA1. This conclusion is based on three lines of evidence. First, silencing Grp170 or Sil1, well-established NEFs of BiP ([@B42]; [@B1]; [@B16]; [@B46]), decreases CTA1 retrotranslocation. Second, overexpression of WT but not a NEF-defective Grp170 stimulates toxin retrotranslocation. Similarly, over­expression of WT but not of a Sil1 mutant that cannot bind to BiP (and thus unlikely to impart NEF activity to BiP) enhances CTA1 retrotranslocation. Third, altering the levels of Grp170 or Sil1 affected toxin--BiP binding, in line with the posited role of NEFs in regulating substrate--BiP interaction. In fact, overexpressing the mutant Grp170 or Sil1 construct decreased CTA1 retrotranslocation, although a precise molecular explanation for these observations is unclear. It is possible that these NEFs normally interact with ERAD components to position the release reaction proximal to the retrotranslocation site. In this scenario, the NEF mutants would act in a dominant-negative manner simply by binding to the ERAD components, thereby preventing the endogenous WT counterparts from properly engaging the ERAD machinery. We note that down-regulating either Grp170 or Sil1 individually did not fully block CTA1 arrival to the cytosol, consistent with the notion that the toxin hijacks multiple NEFs to disengage from BiP. We envision that CT\'s ability to use both NEFs maximizes the efficiency by which it can be released from BiP. This likely leads to more efficient retrotranslocation. Silencing Grp170 and Sil1 simultaneously compromised cellular integrity, thereby precluding us from assessing whether double knockdown of Grp170 and Sil1 perturbed CTA1 retrotranslocation more drastically than the single-knockdown condition.

After NEF-dependent release from BiP, our data also indicate that the toxin is transferred to PDI. We previously demonstrated that a fraction of PDI is localized proximal to the Hrd1 complex by virtue of PDI\'s interaction with Derlin-1 and Hrd1 ([@B2]; [@B26]). Using a redox-driven mechanism, PDI then unfolds CTA1 ([@B41]; [@B11]; [@B43]), a reaction required for toxin retrotranslocation in cells ([@B12]). Although a separate study found that PDI displaces CTA1 from CT ([@B38]), this reaction likely also requires partial unfolding of CTA1 due to extensive interactions between CTA and CTB. There are conflicting results regarding whether PDI also acts as the cellular reductase for generating CTA1 from CTA ([@B30]; [@B24]). Nonetheless, once the CTA1 peptide unfolds, it is primed to transport across a retrotranslocation channel. Previous findings implicated the E3 ligases Hrd1 and gp78 ([@B3]) and Derlin-1 ([@B2]; [@B8]) in playing a critical function during toxin retrotranslocation, whereas a different study demonstrated that Derlin-1 is dispensable in this process ([@B35]). Whether these membrane components serve as the actual channel for transferring CTA1 across the ER membrane is unknown, although yeast Hrd1 has been postulated as the protein conduit for canonical ERAD substrates ([@B5]; [@B37]). Another candidate for conducting CTA1 across the ER membrane is the Sec61 channel used during forward translocation ([@B36]). A reconstituted system using purified components should help to resolve this question.

Other toxins that employ the ERAD pathway can also use BiP and its cochaperones to promote their retrotranslocation into the cytosol. For instance, Shiga toxin uses BiP ([@B10]) and the cochaperone ERdj3 ([@B47]) to mobilize from the ER into the cytosol; this BiP cochaperone has also been found to be important for CTA1 retrotranslocation ([@B25]). In addition, the viral A/B toxin K28 uses BiP and its cochaperones to retrotranslocate into the cytosol during intoxication ([@B18]). The use of BiP and cochaperones by these toxins suggests that the toxins display structural properties inherent in a misfolded protein that are normally handled by this chaperone system. Whereas BiP promotes ER-to-cytosol transport of CT, Shiga toxin, and the K28 toxin, a recent report found that it antagonizes retrotranslocation of the plant toxin ricin ([@B15]), despite the observation that Sel1L facilitates ricin retrotranslocation ([@B33]). Hence how a toxin coopts the BiP/cochaperone system in the ER clearly varies and is dependent on the nature of the toxin.

MATERIALS AND METHODS
=====================

Materials
---------

Polyclonal antibodies against PDI and Hsp90 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), polyclonal Grp170 and Sil1 antibodies from Genetex (Irvine, CA), monoclonal PDI antibodies from Abcam (Cambridge, MA), monoclonal BiP antibody from BD Biosciences (San Jose, CA), and monoclonal FLAG antibody and FLAG antibody--conjugated beads (M2 affinity gel) from Sigma-Aldrich (St. Louis, MO). Polyclonal CTA antibody was produced against denatured CTA purchased from EMD Biosciences (San Diego, CA). Purified CT was purchased from EMD Biosciences, protein G agarose from Thermo Fisher Scientific (Rockford, IL), and protein A agarose beads from Invitrogen (Carlsbad, CA). Polyclonal Derlin-1 antibody was a gift from T. Rapoport (Harvard University, Cambridge, MA).

Constructs
----------

The Grp170-FLAG, G41L Grp170-FLAG, FLAG-Sil1, and GFP-FLAG constructs were generated as described in [@B21]. To generate the FLAG-H241A Sil1 mutant, the corresponding mutation was introduced with an overlapping PCR method using FLAG-Sil1 as a template. For the siRNA-resistant Grp170-FLAG\* construct, the following silent mutations were introduced into the construct by overlapping PCR: 2716-CT[G]{.ul}AA[C]{.ul}AA[A]{.ul}GC[T]{.ul}AA[A]{.ul}TT[C]{.ul}-2733. For the siRNA-resistant FLAG-Sil1\* construct, the following silent mutations were introduced into the construct by overlapping PCR: 613-GC[C]{.ul}CT[G]{.ul}TT[C]{.ul}GA[C]{.ul}CT[G]{.ul}GA[G]{.ul}-630. The underlines denote the introduced silent mutations.

Tissue culture, transfection and drug treatment
-----------------------------------------------

HEK 293T cells were cultured in DMEM with 10% fetal bovine serum and penicillin/streptomycin. The cells were grown to 30% confluency on a 6-or 10-cm dish before transfection with 1 μg/ml polyethylenimine. Cells were typically grown for an additional 24 or 48 h before experimentation. Where indicated, cells were treated with or without 10 nM CT in Hank\'s balanced salt solution (HBSS) for 90 min before experimentation.

siRNA knockdown of Grp170, Sil1, and PDI
----------------------------------------

Cells were grown to 30% confluency on a 6-, 10-, or 15-cm dish and transfected with the indicated siRNA construct for 48 h with the Lipofectamine RNAi MAX reagent (Invitrogen). The sequences of the siRNAs used in this study were Grp170 siRNA \#1 (5′-GCUCAAUAAGGCCAAGUUUTddT-3′; Invitrogen), Grp170 siRNA \#2 (5′-GCCUUUAAAGUGAAGCCAUdTdT-3′; Invitrogen), Sil1 siRNA \#1 (5′-GCUGAUCAACAAGUUCAAUdTdT-3′; Invitrogen), Sil1 siRNA \#2 (5′-GCGCUCUUUGAUCUUGAAUdTdT-3′; Invitrogen), and PDI siRNA (5′-CAACUUUGAAGGGGAGGUCUUdTdT-3\'; Thermo Fisher Scientific).

XBP1 splicing and retrotranslocation assays
-------------------------------------------

These were described previously in [@B44].

Coimmunoprecipitation
---------------------

293T cells were incubated with or without 10 nM CT in HBSS for 90 min, harvested, and lysed in buffer containing 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; pH 7.5, 50 mM), NaCl (150 mM), sucrose (250 mM), MgCl~2~ (2 mM), *N*-ethylmaleimide (10 mM), 1% Triton X-100 or 1% deoxy Big Chap (Sigma-Aldrich), and protease inhibitors for 30 min at 4°C. Cells were centrifuged at 16,000 × *g* for 10 min, and the supernatant was used for immunoprecipitation. Where indicated, FLAG antibody--conjugated beads or a mixture of protein A/G agarose was added to the WCE and incubated at 4°C overnight. The immunocomplex was sedimented, washed, and subjected to SDS--PAGE, followed by immunoblotting with the appropriate antibody.

Δ F508 CFTR steady-state analysis
---------------------------------

Cells reverse transfected with the indicated siRNA were further transfected with the Δ F508 CFTR construct, incubated for 24 h, harvested, and lysed in a buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1% Triton X-100, and 1 mM phenylmethylsulfonyl fluoride. The resulting WCE was incubated with a monoclonal CFTR antibody (M3A7) overnight, followed by capturing of the immune complex with Protein G magnetic beads (Life Technologies, Grand Island, NY). The bound proteins were eluted with SDS sample buffer and analyzed by immunoblotting with a CFTR antibody.
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CFTR

:   cystic fibrosis transmembrane conductance regulator

CT

:   cholera toxin

CTA

:   cholera toxin catalytic A subunit

CTB

:   cholera toxin catalytic B subunit

DTT

:   dithiothreitol

ECL

:   enhanced chemiluminescence

ER

:   endoplasmic reticulum

ERAD

:   ER-associated degradation

GFP

:   green fluorescent protein

NEF

:   nucleotide exchange factor

PDI

:   protein disulfide isomerase

s

:   spliced

siRNA

:   small interfering RNA

u

:   unspliced

WCE

:   whole cell extract

WT

:   wild type.
